Mouad Edderkaoui, PhD

Adjunct Assistant Professor, David Geffen School of Medicine at UCLA

Dr. Edderkaoui investigates the mechanisms of initiation and progression of pancreatic cancer in order to develop prevention and treatment strategies. His work during the last few years focused on the mechanism through which growth factors (especially IGF-I) and extracellular matrix proteins protect pancreatic cancer cells from apoptosis. Specifically, Dr. Edderkaoui identified novel pro-survival roles of reactive oxygen species produced by NADPH oxidase in pancreatic cancer cells through inhibition of protein tyrosine phosphatase and activation of the Jak2/STAT and Akt pathways. Recently, Dr. Edderkaoui was interested in investigating the mechanisms through which major risk factors of pancreatic cancer such as smoking and chronic pancreatitis induce the disease; especially, the regulation of the epithelial to mesenchymal transition pathway and the induction of stem cell markers’ expression by these risk factors in mouse models of pancreatic cancer. Dr. Edderkaoui previously a CURE: DDRCC Associate Member, has secured independent funding and consequently has now been advanced to membership. Dr. Edderkaoui received a CURE: DDRCC Pilot and Feasibility Study award in 2008 and 2009.